(SRTR) to publish program-specific reports (PSRs) that can be "accurately and efficiently" used and understood. In December 2016, SRTR released a 5-tier system to improve the accessibility of 1-year posttransplant program evaluations already included in the PSRs. The statistical summary measures included in the PSRs (hazard ratios [HRs] and 95% confidence intervals [CIs]) were considered too challenging for nontechnical stakeholders, such as patients and families, to understand.
| INTRODUC TI ON
The Organ Procurement and Transplantation Network (OPTN)
Final Rule requires the Scientific Registry of Transplant Recipients (SRTR) to publish program-specific reports (PSRs) that can be "accurately and efficiently" used and understood. In December 2016, SRTR released a 5-tier system to improve the accessibility of 1-year posttransplant program evaluations already included in the PSRs. The statistical summary measures included in the PSRs (hazard ratios [HRs] and 95% confidence intervals [CIs]) were considered too challenging for nontechnical stakeholders, such as patients and families, to understand. 1, 2 Instead, a more accessible approach would transform the statistical summary measures into a limited number of categories. SRTR previously used a 3-tier system based on statistical hypothesis testing. The 3-tier system poorly differentiated program evaluations and may have obscured potentially relevant differences, especially for small-to-moderately sized programs. 3 The 5-tier system was designed to better differentiate posttransplant evaluations, and, in kidney transplant, it reduced the variability of program-specific HRs within a tier by nearly 80%. 3 Because the 5-tier system narrowed the outcome differences across tiers, programs were more likely to change tiers over time than they were under the previous 3-tier system. 4 The higher variability in tier assignment over time and long duration from listing to transplant, especially for kidney candidates, 5 could attenuate the association between tier assignment when a candi- In these situations, the PSR release date was approximated by the prior release of the corresponding biannual PSR cycle. Factors with nonzero effects in either the living or deceased donor PSR models were included. The value of deceased donor-specific factors for living donor transplants was set to the median for continuous factors and the reference level for categorical factors.
| MATERIAL S AND ME THODS
Multiple imputation with 10 iterations accounted for missing data. 9 The effects of the continuous factors were estimated with the use of penalized splines. Robust standard errors accounted for correlation among transplants at the same program. The supplementary materials include a sensitivity analysis for the effect of an additional tier in the traditional 3-tier system based on statistical hypothesis testing.
All analyses were completed in R v3.3.3. 10 Cox proportional hazard models were estimated with the "survival" package, 11 and multiple imputation was completed with the "mice" package. Table S1 ). Most liver (80% ; Table S2 ), lung (88% ; Table S3 ), and heart (79% ; Table S4 ) recipients also underwent transplant within 1 year of listing.
| Kidney transplant
An additional tier at listing had a 4% lower hazard ( 
| Liver transplant
An additional 1 tier at listing was associated with a 7% lower hazard 
| Lung transplant
An additional tier at listing was associated with a 10% lower hazard 
| Heart transplant
Tier assignment at listing (Figure 4 , left) and the 5-tier score at listing (Figure 4 , right) were not associated with eventual posttransplant outcomes in heart transplant. Thus, heart recipients who listed at programs with better posttransplant evaluations did not experience better or worse outcomes than heart recipients who listed at programs with worse posttransplant evaluations.
| D ISCUSS I ON
For liver and lung recipients, posttransplant evaluations at listing were moderately associated with eventual posttransplant outcomes, F I G U R E 2 Liver transplant. The association of the hazard ratio at listing and the 5-tier score at listing with eventual posttransplant 1-year liver graft survival. The dashed lines are the pointwise 95% confidence intervals, and the dotted line is a hazard ratio of 1. The 5-tier score is the underlying continuous score used to categorize programs into the 5-tier system. The x-axis tick marks for the 5-tier score correspond to the cutpoints used to categorize programs into tiers; for example, programs with a 5-tier score >0.875 were categorized as tier 5
Linear Trend
Hazard average to average evaluations but attenuated or no differences between programs with average to below average evaluations. In heart transplant, a better tier assignment at listing was not associated with better or worse outcomes, and it is not clear that any categorization system would be associated with posttransplant outcomes in heart transplant because the 5-tier score at listing had no association with eventual outcomes.
We performed a sensitivity analysis that repeated the primary analysis for the traditional 3-tier system based on statistical hypothesis testing. The analysis for the 3-tier system showed larger effects but also higher variability for 1 additional tier at listing than the associations for the 5-tier system (Table S5 ). The larger effect size is not surprising because 1 additional tier in the 3-tier system corresponds to ≈2 additional tiers in the 5-tier system, while the higher variability is likely explained by the smaller number of recipients in tiers 1 and 3.
There are at least 2 frameworks for understanding the usefulness of posttransplant evaluations: first, the ability of posttransplant evaluations to predict eventual outcomes, and second, creating incentives for quality improvement. The former framework has a direct role in patient decision-making because an association with eventual posttransplant outcomes would create an incentive for patients to list at programs with good posttransplant evaluations. In contrast, the latter framework is only indirectly related to patient outcomes through the potentially better outcomes at all programs due to the incentive for quality improvement.
Unfortunately, these frameworks may work in opposition to each other; that is, an incentive for quality improvement could attenuate For each organ, the differences in eventual posttransplant outcomes were relatively small, especially compared with the differences suggested by the posttransplant evaluations. However, smaller differences were expected because the predictive performance of statistical models is almost always worse for future outcomes than for outcomes used to estimate the model. 19 For example, a tier-5
program had an 81% probability of a truly better HR than a tier-3
program within a PSR cycle. 3 A prospective, rather than within-PSR cycle, probability would naturally be lower because program care
can change due to quality improvement efforts and/or staff turnover. However, the association in liver and lung transplant suggests that the 5-tier system remained predictive despite these challenges. 
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While these results may partially reflect changes in programs over time, the variability in tier assignment over time is not an inherently informative metric for evaluating the categorization of posttransplant outcomes. 4 The 5-tier system was explicitly designed to improve the differentiation of program performance at the cost of a higher misclassification rate. 3 As a direct consequence, the 5-tier system would be expected to be more variable in tier assignment over time because better differentiation was achieved by narrow- given lack of data on referral and evaluation.
Posttransplant evaluations at listing and, specifically, the 5-tier system were associated with eventual posttransplant outcomes in liver and lung transplant but not in kidney or heart transplant. Thus, the 5-tier system differentiated eventual recipient outcomes in liver and lung transplant that were unexplained by measured recipient and donor risk factors. 
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